Literature DB >> 23956362

eComment. Potential therapeutic agents in vasoplegic syndrome after cardiac surgery.

Senol Yavuz, Faruk Toktas, Suleyman Surer, Cuneyt Eris.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23956362      PMCID： PMC3745162          DOI： 10.1093/icvts/ivt315

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN： 1569-9285


× No keyword cloud information.
  5 in total

Review 1.  Vasoplegic syndrome--the role of methylene blue.

Authors:  Ganesh Shanmugam
Journal:  Eur J Cardiothorac Surg       Date:  2005-09-06       Impact factor: 4.191

2.  Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?

Authors:  Rainer G Leyh; Theo Kofidis; Martin Strüber; Stefan Fischer; Karsten Knobloch; Bjoern Wachsmann; Christian Hagl; Andre R Simon; Axel Haverich
Journal:  J Thorac Cardiovasc Surg       Date:  2003-06       Impact factor: 5.209

3.  Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension.

Authors:  Eiki Tayama; Tomohiro Ueda; Takahiro Shojima; Koji Akasu; Takeshi Oda; Shuji Fukunaga; Hidetoshi Akashi; Shigeaki Aoyagi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2007-08-17

4.  Pre-existing endothelial cell activation predicts vasoplegia after mitral valve surgery.

Authors:  Kirsten A Kortekaas; Jan H N Lindeman; Marlies E J Reinders; Meindert Palmen; Robert J M Klautz; Philip G de Groot; Mark Roest
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-04

5.  A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery.

Authors:  Alberto Noto; Salvatore Lentini; Antonio Versaci; Massimiliano Giardina; Domenica Claudia Risitano; Roberto Messina; Antonio David
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.